extended-release opioid pain relievers

Two FDA expert panels rejected a new extended-release oxycodone pill. Some of their findings are reasonable, even if you don't agree with them. But one reason is very far beyond stupid. Especially since they refused to learn from history. 
A debate that s been squarely in the headlines in recent weeks about how to manage the rapidly growing problem of opiate addiction in the U.S., is now heating up even more. This is due to a recent JAMA viewpoint, as well as statements made by an advocacy group
As we have discussed previously, deaths from drug overdoses, particularly opioids, are on the rise. In an effort to